KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomarin Pharmaceutical (BMRN) Share-based Compensation (2016 - 2025)

Historic Share-based Compensation for Biomarin Pharmaceutical (BMRN) over the last 17 years, with Q3 2025 value amounting to $49.3 million.

  • Biomarin Pharmaceutical's Share-based Compensation rose 1328.15% to $49.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $186.4 million, marking a year-over-year decrease of 884.66%. This contributed to the annual value of $201.6 million for FY2024, which is 266.93% down from last year.
  • As of Q3 2025, Biomarin Pharmaceutical's Share-based Compensation stood at $49.3 million, which was up 1328.15% from $47.5 million recorded in Q2 2025.
  • Biomarin Pharmaceutical's Share-based Compensation's 5-year high stood at $58.2 million during Q1 2024, with a 5-year trough of $37.7 million in Q1 2025.
  • Over the past 5 years, Biomarin Pharmaceutical's median Share-based Compensation value was $49.0 million (recorded in 2021), while the average stood at $49.3 million.
  • Its Share-based Compensation has fluctuated over the past 5 years, first soared by 2197.63% in 2021, then crashed by 3527.79% in 2025.
  • Biomarin Pharmaceutical's Share-based Compensation (Quarter) stood at $43.9 million in 2021, then rose by 6.48% to $46.7 million in 2022, then increased by 17.38% to $54.9 million in 2023, then fell by 5.35% to $51.9 million in 2024, then fell by 5.11% to $49.3 million in 2025.
  • Its Share-based Compensation was $49.3 million in Q3 2025, compared to $47.5 million in Q2 2025 and $37.7 million in Q1 2025.